Sanders Urges Denmark to Pressure Novo Nordisk on Lowering Drug Prices
(Bloomberg) -- Bernie Sanders urged Denmark to force its most valuable company, Novo Nordisk A/S, to lower its drug prices, in a letter submitted by the US senator to one of the Nordic country’s largest newspapers.
Most Read from Bloomberg
Trump Vows ‘Day One’ Executive Order Targeting Offshore Wind
Macron Puts French Banks in Play With Plan to Transform Europe
Tesla Rehires Some Supercharger Workers Weeks After Musk’s Cuts
China to Start $138 Billion Bond Sale on Friday to Boost Economy
Flood of China Used Cooking Oil Spurs Call to Hike US Levies
Sanders, who chairs the Senate’s Health, Education, Labor and Pensions Committee, called on Danes to pressure Novo to “significantly reduce the outrageously high prices for Ozempic and Wegovy in the US and other parts of the world,” according to the letter, published by the Politiken newspaper on Monday.
Read more: Ozempic Maker Novo Nordisk Has Denmark’s Economy Hooked
Sanders has also called on Novo directly to lower its prices and has asked the drugmaker to reply to a series of questions on costs and manufacturing. The company is currently unable to produce enough of its Wegovy weight-loss treatment to meet demand, and people are also hording diabetes drug Ozempic, which includes the same active ingredient.
Sanders, who wrote in the Monday letter that he admires Denmark’s welfare system, said Novo charges roughly ten times more for Ozempic in the US compared with European countries. “Help the American people do something about the obesity and diabetes epidemic we are facing,” the senator said.
Most Read from Bloomberg Businessweek
Cheap Prison Labor Is Keeping People Locked Up Longer, Suit Alleges
How the ‘Harvard of Trading’ Ruined Thousands of Young People’s Lives
‘The Caitlin Clark Effect Is Real,’ and It’s Already Changing the WNBA
©2024 Bloomberg L.P.
